Prevalence of hepatitis G virus RNA in French blood donors and recipients

Loiseau, Pascale; Mariotti, Martine; Corbi, C.; Ravera, N; Girot, Robert; Thauvin, M; Portelette, E; Mariette, Xavier; Roudot‐Thoraval, Françoise; Benbunan, M; Lefrère, Jean‐Jacques

doi:10.1046/j.1537-2995.1997.37697335161.x

Cited by 48 publications

(38 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The frequency of GBV-C/HGV infection observed in this study of blood donors is higher than the rates of 4-5.5% of blood donors with prior contact with GBV-C/ HGV obtained in the USA Gutierrez et al, 1997], lower than the data reported in Brazil or Africa for GBV-C/HGV RNA (9% and 14%) and anti-E2 (19.5% and 20.3%) Bassit et al, 1997;Ross et al, 1998], and slightly higher but consistent with the prevalence published in Europe [Jarvis et al, 1996;Prati et al, 1997;Tacke et al, 1997;Ross et al, 1998] and in continental France [Loiseau et al, 1997]. The prevalence of GBV-C/HGV in Martinique blood donors is much higher than the prevalence of HCV, as reported elsewhere.…”

Section: Discussionsupporting

confidence: 82%

Infection with GB virus C/hepatitis G virus among blood donors and hemophiliacs in Martinique, a Caribbean Island

et al. 1999

View full text Add to dashboard Cite

GB virus C/hepatitis G virus (GBV-C/HGV) RNA was detected by reverse transcription-polymer- ase chain reaction with primers derived from the nonstructural region 3 (NS3) in 9 (4.1%) of 221 blood donors and 2 of 20 (10%) hemophilia patients in Martinique, French West Indies. Anti-E2 antibodies were found in sera from 33 (14.9%) of the blood donors and 5 (25%) of the hemophiliacs. None of the subjects was positive for both GBV-C/HGV RNA and anti-E2. Among the 20 hemophiliacs, 12 (60%) had anti-HCV antibodies and 7 (35%) were positive for HCV RNA by PCR. All patients positive for HCV markers belonged to the group of 13 patients exposed previously to blood factor concentrates that were not activated virally. Nucleotide sequences of the 5'-untranslated region (5'UTR) of the GBV-C/HGV genome were obtained for the 10 NS3 PCR positive samples. Phylogenetic comparison of these isolates with reference isolates published previously showed a strong homology with European and American GBV-C/HGV strains, 8 isolates belonging to the genotype 2a and 1 isolate to the type 2b. The isolate from 1 blood donor was identified as subtype 1a, indicating the presence of West African type strains.

show abstract

Section: Discussionsupporting

confidence: 82%

Infection with GB virus C/hepatitis G virus among blood donors and hemophiliacs in Martinique, a Caribbean Island

et al. 1999

View full text Add to dashboard Cite

show abstract

“…The prevalence of HGV was exactly the same in our 2 groups and was a little lower than the 4.2% prevalence among blood donors in France. 32 It is unlikely that HGV could play a pathogenic role in urticaria because the prevalence was low and did not differ between the 2 groups. The role of HGV has also been ruled out in patients with lichen planus, 22,33 but a slight increase in the prevalence of HGV was described in patients with porphyria cutanea tarda, 34 as 8.9% of 124 patients had positive results on HGV tests.…”

Section: Commentmentioning

confidence: 95%

Chronic Urticaria Is Not Significantly Associated With Hepatitis C or Hepatitis G Infection

Cribier¹,

Santinelli²,

Schmitt³

et al. 1999

Arch Dermatol

View full text Add to dashboard Cite

“…The model picks up a known virus, the GBV-C/HGV flavivirus. This virus is endemic in apparently healthy human blood donors at a range of 1-4.5% as shown by NAT testing in the US, France, Germany, and other countries [27][28][29][30][31][32][33][34]39]. It is not the purpose of this paper to reopen the discussion on the pathogenicity of HGV-C/HGV.…”

Section: Discussionmentioning

confidence: 98%

“…It is not the purpose of this paper to reopen the discussion on the pathogenicity of HGV-C/HGV. We and many others have shown that GBV-C is unlikely to be involved in disease processes [28,30,34,39] and is thus tolerated in the human blood supply. We are also aware that GBV-C/HGV can be inactivated by pathogen reduction systems [2,4].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A General Change of the Platelet Transfusion Policy from Apheresis Platelet Concentrates to Pooled Platelet Concentrates is Associated with a Sharp Increase in Donor Exposure and Infection Rates

Heuft¹,

Mende²,

Blasczyk³

2008

Transfus Med Hemother

View full text Add to dashboard Cite

Background: We compare the actual with the potential donor exposure and possible infection rates in the Hanover Medical School (MHH) platelet (PLT) transfusion recipients if the current MHH standard of apheresis PLT concentrate (A-PC) supply would be replaced by a pooled PLT concentrate (P-PC) transfusion regimen. Donors, Patients, and Methods: The electronic records of the MHH Institute of Transfusion Medicine and the MHH Department of Medical Controlling were evaluated to assess the development of PLT needs and supply at MHH from 2003–2006. For 2006, we evaluated all PLT transfusion recipients with respect to their overall transfusion needs, classified them for low and high PLT transfusion needs, and related them to the diagnostic groups that underlie their PLT demands. We assumed a P-PC preparation procedure using 4 whole blood-derived buffy coats for all calculations for potential donor exposure. To predict the possible infection rates of an unrecognized viral infection with low prevalence in the general population to A-PC or to P-PC recipients and the influence of neutralizing agent specific antibodies (NAB), we established a mathematical contamination/ infection model based on the current PLT transfusion mode and data about GBV-C virus infection among Hanover blood donors. Results: From 2003 to 2006, the 1,300–1,400 persons comprising MHH apheresis donor pool covered a 36% increase in PC transfusions. The exclusive use of P-PCs instead of A-PC would require a total of 36,240–49,276 whole blood donations to meet MHH demands, corresponding to a more than 1 log step increase in donor exposure. For individual hematological patients, the change to P-PCs would imply an 80–125%, for individual surgical patients a 40–50% higher donor exposure. Our infection model revealed an approximately 4 times higher infection. Conclusions: A change to P-PC would imply a more than one log step higher donor exposure, and an unrecognized infection with a prevalence around 1% leads to an up to 4 times higher infection rate. A general change in the PC transfusion policy that favors P-PCs is dangerous and must be avoided.

show abstract

Prevalence of hepatitis G virus RNA in French blood donors and recipients

Abstract: The pathological significance of HGV infection remains unelucidated, and the classification of HGV as a new hepatitis virus was perhaps premature.

Cited by 48 publications

References 13 publications

Infection with GB virus C/hepatitis G virus among blood donors and hemophiliacs in Martinique, a Caribbean Island

Infection with GB virus C/hepatitis G virus among blood donors and hemophiliacs in Martinique, a Caribbean Island

Chronic Urticaria Is Not Significantly Associated With Hepatitis C or Hepatitis G Infection

A General Change of the Platelet Transfusion Policy from Apheresis Platelet Concentrates to Pooled Platelet Concentrates is Associated with a Sharp Increase in Donor Exposure and Infection Rates

Contact Info

Product

Resources

About